Dr. Dolsten was most recently CSO of Pfizer and has served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals Appointment follows the transition ...

Trump isn’t popular in Australia, but he is a highly influential cultural figure. How will his reelection affect Australia’s domestic politics as it approaches a federal election by May 2025?

There are already other business ventures that use the Wyeth name, including an apartment complex in Cambridge, Massachusetts, and a pharmaceutical company founded in Pennsylvania, the family's ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to ...

Trump told reporters on Tuesday that sectoral tariffs on pharmaceuticals and semiconductor chips would also start at "25 per cent or higher, and it will go very substantially higher over the ...

Trump told reporters at his Mar-a-Lago estate in Florida on Tuesday that sectoral tariffs on pharmaceuticals and semiconductor chips would also start at "25% or higher", rising substantially over ...

Irish exports were valued at a record €223.8 billion last year, with medical and pharmaceutical products contributing heavily to the total. Compared to 2023, the value of exports was up 14% ...

Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks. The stock market may have registered losses on Friday ...

The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.